Similar studies for GEO DataSets (Select 200157106) - GEO DataSets

Links from GEO DataSets

Items: 20

Select item 2001571061.

The transcriptional equilibration between androgen receptor and MYC signatures during prostate cancer transition centralizes on a distal developmental super-enhancer circuitry (4C-Seq)

(Submitter supplied) We used RNA-Seq, ChIP-Seq and 4C-Seq to assess the role of MYC in the transcriptional repression induced by DHT in prostate cancer.

Organism:: Homo sapiens

Type:: Other

Platform:: GPL16791
2 Samples

Download data: WIG

Series

Accession:: GSE157106

ID:: 200157106

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 2001579742.

The transcriptional equilibration between androgen receptor and MYC signatures during prostate cancer transition centralizes on a distal developmental super-enhancer circuitry (HiChIP)

(Submitter supplied) We used RNA-Seq, ChIP-Seq, 4C-Seq and HiChIP to assess the role of MYC in the transcriptional repression induced by DHT in prostate cancer.

Organism:: Homo sapiens

Type:: Other

Platform:: GPL16791
3 Samples

Download data: TXT

Series

Accession:: GSE157974

ID:: 200157974

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 2001571073.

The transcriptional equilibration between androgen receptor and MYC signatures during prostate cancer transition centralizes on a distal developmental super-enhancer circuitry

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing; Other

Platforms:: GPL24676 GPL16791 GPL18573
47 Samples

Download data: TXT, WIG

Series

Accession:: GSE157107

ID:: 200157107

PubMed Full text in PMC Similar studies

Select item 2001571054.

The transcriptional equilibration between androgen receptor and MYC signatures during prostate cancer transition centralizes on a distal developmental super-enhancer circuitry (ChIP-Seq)

(Submitter supplied) We used RNA-Seq, ChIP-Seq and 4C-Seq to assess the role of MYC in the transcriptional repression induced by DHT in prostate cancer.

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing

Platforms:: GPL16791 GPL18573
14 Samples

Download data: TXT

Series

Accession:: GSE157105

ID:: 200157105

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 2001571045.

The transcriptional equilibration between androgen receptor and MYC signatures during prostate cancer transition centralizes on a distal developmental super-enhancer circuitry (RNA-Seq)

(Submitter supplied) We used RNA-Seq, ChIP-Seq and 4C-Seq to assess the role of MYC in the transcriptional repression induced by DHT in prostate cancer.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platforms:: GPL24676 GPL16791
28 Samples

Download data: TXT

Series

Accession:: GSE157104

ID:: 200157104

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

Select item 2001484006.

Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing

Platform:: GPL16791
219 Samples

Download data: NARROWPEAK

Series

Accession:: GSE148400

ID:: 200148400

PubMed Full text in PMC Similar studies

Select item 2001483977.

Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation [RNA-seq]

(Submitter supplied) The androgen receptor (AR) antagonist darolutamide has very recently been approved for the treatment of non-metastatic castration resistant prostate cancer (PCa). Here we determined the genome-wide effects of darolutamide on cis-acting regulatory elements involved in androgen signaling with a focus on enhancer and super-enhancer (SE) regions. Darolutamide strongly depleted the AR from regulatory elements and abolished the AR transcriptional signaling. more...

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL16791
112 Samples

Download data: TSV

Series

Accession:: GSE148397

ID:: 200148397

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

Select item 2001483588.

Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation [ChIP-seq]

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing

Platform:: GPL16791
107 Samples

Download data: NARROWPEAK

Series

Accession:: GSE148358

ID:: 200148358

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 2002232519.

Gene expression profiling in prostate cancer cell line LNCaP.

(Submitter supplied) Global definition of androgen and anti-androgen effects on LNCaP transcriptomes using Affymetrix U133A oligonucleotide microarray. LNCaP in androgen-depleted medium was treated with androgen (DHT) and anti-androgen (CPA) for different time points (2 hours, 4 hours, 8 hours, and 24 hours). Untreated or Vehicle (Ethanol) treated samples as control.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL96
22 Samples

Download data

Series

Accession:: GSE223251

ID:: 200223251

Select item 20008443210.

Analysis of active enhancers and direct androgen receptor target genes in VCaP prostate cancer cells

(Submitter supplied) Androgen receptor (AR) is typically overexpressed in castration-resistant prostate cancer (CRPC). CRPC-derived VCaP cells display an excessive number of chromatin AR-binding sites (ARBs). This study analyzed direct transcription programs of the AR, the prevalence of AR enhancers and the transcriptional regulators involved in the regulation of at the enhancer regions. The analysis utilized global nuclear run-on sequencing (GRO-seq). more...

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing

Platform:: GPL11154
20 Samples

Download data: BED, BEDGRAPH, XLSX

Series

Accession:: GSE84432

ID:: 200084432

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

Select item 20007399511.

Overexpression of c-Myc antagonises transcriptional output of the androgen receptor in prostate cancer

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by array; Genome binding/occupancy profiling by high throughput sequencing

Platforms:: GPL11154 GPL10558
44 Samples

Download data: BIGWIG

Series

Accession:: GSE73995

ID:: 200073995

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20007399412.

Overexpression of c-Myc antagonises transcriptional output of the androgen receptor in prostate cancer [ChIP-Seq]

(Submitter supplied) c-Myc overexpression LNCaP cells were treated with R1881 or R1881+Doxycycline (to induce c-Myc overexpression) and ChIP-seq studies were performed using antibodies against c-Myc, AR, H3K4me1, H3K4me3, H3K27ac and H3K27m3 Prostate cancer is the most common non-cutaneous cancer in men. The androgen receptor (AR) a ligand-activated transcription factor, constitutes the main drug target for advanced cases of the disease. more...

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing

Platform:: GPL11154
20 Samples

Download data: BIGWIG

Series

Accession:: GSE73994

ID:: 200073994

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 20007391713.

Overexpression of c-Myc antagonises transcriptional output of the androgen receptor in prostate cancer [expression]

(Submitter supplied) Prostate cancer is the most common non-cutaneous cancer in men. The androgen receptor (AR) a ligand-activated transcription factor, constitutes the main drug target for advanced cases of the disease. However, a variety of other transcription factors and signalling networks have been shown to be altered in patients and to influence AR activity. The oncogenic transcription factor c-Myc has been studied extensively in multiple malignancies, but its impact on AR activity in prostate cancer remains elusive. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL10558
24 Samples

Download data: TXT

Series

Accession:: GSE73917

ID:: 200073917

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20022889714.

Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor Through cMYC Repression and Recruitment of the DREAM Complex

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing; Other; Expression profiling by high throughput sequencing

Platforms:: GPL16791 GPL24676
101 Samples

Download data: NARROWPEAK, TXT

Series

Accession:: GSE228897

ID:: 200228897

PubMed Full text in PMC Similar studies

Select item 20022889615.

Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor Through cMYC Repression and Recruitment of the DREAM Complex [CUT&RUN]

(Submitter supplied) The androgen receptor (AR) pathway regulates key cell survival programs in prostate epithelium. Targeting the AR has a remarkable therapeutic index and represents a near-universal driver and therapeutic vulnerability in metastatic prostate cancer. Though most approaches directed toward the AR focus on inhibiting AR signaling, laboratory and now clinical data have shown that high dose, supraphysiological androgen treatment (SPA), results in growth repression and improved out-comes in subsets of prostate cancer patients. more...

Organism:: Homo sapiens

Type:: Other

Platform:: GPL16791
21 Samples

Download data: NARROWPEAK

Series

Accession:: GSE228896

ID:: 200228896

PubMed Full text in PMC Similar studies

Select item 20022889516.

Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor Through cMYC Repression and Recruitment of the DREAM Complex [ChIP-seq]

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing

Platform:: GPL16791
14 Samples

Download data: NARROWPEAK

Series

Accession:: GSE228895

ID:: 200228895

PubMed Full text in PMC Similar studies

Select item 20022548117.

Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor Through cMYC Repression and Recruitment of the DREAM Complex [RNA-seq]

(Submitter supplied) The androgen receptor (AR) pathway regulates key cell survival programs in prostate epithelium. Targeting the AR has a remarkable therapeutic index and represents a near-universal driver and therapeutic vulnerability in metastatic prostate cancer. Though most approaches directed toward the AR focus on inhibiting AR signaling, laboratory and now clinical data have shown that high dose, supraphysiological androgen treatment (SPA), results in growth repression and improved outcomes in subsets of prostate cancer patients. more...

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platforms:: GPL16791 GPL24676
66 Samples

Download data: TXT

Series

Accession:: GSE225481

ID:: 200225481

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20016126818.

Stable overexpression of MED19 in androgen-dependent LNCaP cells promotes growth under conditions of androgen deprivation

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing

Platform:: GPL20301
72 Samples

Download data: BIGWIG

Series

Accession:: GSE161268

ID:: 200161268

PubMed Full text in PMC Similar studies

Select item 20016117019.

Transcriptome profiles of alternative MED19 LNCaP and control LNCaP cells cultured under androgen deprivation with vehicle or R1881

(Submitter supplied) We report the application of ChIP and RNA sequencing to identify the mechanism whereby stable overexpression of MED19 in androgen-dependent LNCaP cells promotes growth under conditions of androgen deprivation. We determined the MED19 and AR transcriptomes and cistromes in control and MED19 LNCaP cells. We also examined genome-wide H3K27 acetylation in both the absence and presence of androgens. We found that MED19 overexpression selectively alters AR occupancy, H3K27 acetylation, and gene expression. more...